CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Sorafenib tablets

Last Updated: July 31, 2006
Result type: Reports
Project Number: SR0071-000
Product Line: Reimbursement Review

Generic Name: Sorafenib tablets

Brand Name: Nexavar

Manufacturer: Bayer Inc.

Therapeutic Area: Cancer, Renal cell carcinoma

Indications: Cancer, Renal cell carcinoma

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 28, 2007

Recommendation Type: Do not list